Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias

Biologics: Targets and Therapy

Volumn 2, Issue 3, 2008, Pages 419-431

  Roccaro, Aldo M ^a   Ghobrial, Irene M ^a   Blotta, Simona ^a   Treon, Steven P ^a   Malagola, Michele ^b   Anderson, Kenneth C ^a   Richardson, Paul G ^a   Russo, Domenico ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Monoclonal gammopaties; Targeted therapies

Indexed keywords

EID: 77949657551     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Abdelkefi A, Ladeb S, Torjman L, et al. 2008. Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicentre randomized clinical trial. Blood, 111:1805-10.
2. Anderson K, Richardson P, Chanan-Khan A, et al. 2006. Single-agent Bortezomib in previously untreated multiple myeloma (MM): Results of a phase II multicenter study [abstract]. J Clin Oncol, 18S:7504.
3. Attal M, Harousseasu JL, Leyvraz S, et al. 2006. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood, 108:3289-94.
4. Badros AZ, Goloubeva O, Rapoport AP, et al. 2005. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol, 23:4089-99.
5. Bensinger W, Jagannath A, Becker P, et al. 2006. Phase I dose escalation study of a fully human, antagonist anti-CD40 antibody, HCD122 (Formerly CHIR-12.12) in patients with relapsed and refractory multiple myeloma [abstract]. Blood, 108:3575.
6. Blade J, San Miguel J, Nagler A, et al. 2007. The prolonged time to progression with pegylated liposomal doxorubicin + Bortezomib versus Bortezomib alone in relapsed or refractory multiple myeloma is unaffected by extent of prior therapy or previous anthracycline exposure [abstract]. Blood, 110:410.
7. Chanan-Khan AA. 2004. Bcl-2 antisense therapy in multiple myeloma. Oncology (Huntington), 18:21-4.
8. Chanan-Khan AA, Richardson PG, Alsina M, et al. 2005. Phase 1 clinical trial of KOS-953 + Bortezomib (BZ) in relapsed refractory multiple myeloma (MM) [abstract]. Blood, 106:362.
9. Chauhan D, Catley L, Li G, et al. 2005. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell, 8:407-19.
10. Chauhan D, Singh A, Brahmandam M, et al. 2007. Combination of proteasome inhibitors Bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood, 111:1654-64.
11. Davies FE, Raje N, Hideshima T, et al. 2001. Thalidimide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98:210-16.
12. Davies FE, Wu P, Srikanth M, et al. 2006. The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with minimal toxicity compared to velcade alone (V) and velcade plus dexamethasone [abstract]. Blood, 108:3537.
13. Deocampo R, Rich R, Ryoo JJ, et al. 2002. Immunomodulatory drug CC- 5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100:3063-7.
14. Dimopoulos MA, Tsatalas C, Zomas A, et al. 2003. Treatment of Waldenström's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol, 30:265-9.
15. Dimopoulos MA, Spencer A, Attal M, et al. 2005. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM010) [abstract]. Blood, 106:6.
16. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. 2005. Treatment of relapsed or refractory Waldenström's macroglobulinemia with Bortezomib. Haematologica, 90:1655-8.
17. Dimopoulos M, Anagnostopoulos A, Kyrtsonis M, et al. 2006. Primary treatment of Waldenströms macroglobulinemia (WM) with dexamethasone, rituximab and cyclophosphamide [abstract]. Blood, 108:128.
18. Dredge K, Marriott JB, Macdonald CD, et al. 2002. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer, 87:1166-72.
19. Elsawa S, Novak A, Konopleva M, et al. 2006. Preferential inhibition of malignant cell growth by CDDO in Waldenströms macroglobulinemia [abstract]. Blood, 108:2528.
20. Facon T, Mary J, Harousseau J, et al. 2006. Superiority of melphalanprednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract]. J Clin Oncol, 18S:1.
21. Francis LK, Alsayed Y, Leleu X, et al. 2006. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino- 17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res, 12:6826-35.
22. Gertz MA, Geyer SM, Badros A, et al. 2005. Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenström's macroglobulinemia. Clin Lymphoma, 5:282-4.
23. Gertz MA, Blood E, Kaminer LS, et al. 2004. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma, 45:2047-55.
24. Ghobrial IM, Rajkumar SV. 2003. Management of thalidomide toxicity. J Support Oncol, 1:194-205.
25. Ghobrial I, Fonseca R, Greipp PR, et al. 2004. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenström macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer, 101:2593-8.
26. Harousseau JL, Attal M, Leleu X, et al. 2006. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica, 91:1498-505.
27. Hatjiharissi E, Ho A, Xu L, et al. 2006. Preclinical in vitro and in vivo evidence support a therapeutic role for the CD70 directed monoclonal antibody (SGN-70) in Waldenströms macroglobulinemia (WM) [abstract]. Blood, 108:2490.
28. Hatjiharissi E, Ngo H, Leontovic AA, et al. 2007. Proteomic analysis of Waldenström macroglobulinemia. Cancer Res, 67:3777-84.
29. Hideshima T, Chauhan D, Shima Y, et al. 2000. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96:2943-50.
30. Hideshima T, Chauhan D, Podar K, et al. 2001. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol, 28:607-12.
31. Hideshima T, Bergsagel PL, Kuehl WM, et al. 2004a. Advances in biology of multiple myeloma: clinical applications. Blood, 104:607-18.
32. Hideshima T, Podar K, Chauhan D, et al. 2004b. p38 MAPK inhibition enhances PS-341 (Bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene, 23:8766-76.
33. Hideshima T, Catley L, Yasui H, et al. 2006. Perifosine, an oral bioactive novel alkylphospholipid, inhibts Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood, 107:4053-62.
34. Hu L, Shi Y, Hsu JH, et al. 2003. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood, 101:3126-35.
35. Hunter Z, Boxer M, Kahl B, et al. 2006. Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: results of WMCTG trial 02-079 [abstract]. J Clin Oncol, 24:7523.
36. Hussein M, Berenson J, Niesvisky R, et al. 2006. Results of a phase I trial of SGN-40 (Anti-huCd40 mAb) in patients with relapsed multiple myeloma [abstract]. Blood, 108:3576.
37. Jagannath S, Barlogie B, Berenson J, et al. 2004. A phase 2 study of two doses of Bortezomib in relapsed or refractory myeloma. Br J Haematol, 127:165-72.
38. Jagannath S, Richardson PG, Barlogie B, et al. 2006. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to Bortezomib alone. Haematologica, 91:929-34.
39. Kastritis E, Anagnostopoulos A, Roussou M, et al. 2007. Treatment of light chain (AL) amyloidosis with the combination of Bortezomib and dexamethasone. Haematologica, 92:1351-58.
40. Knop S, Gerecke C, Topp M, et al. 2006. Lenalidomide (revlimid), adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma fi rst results of a german multicenter Phase I/II trial [abstract]. Blood, 108:408.
41. Kumar S, Rajkumar SV. 2006. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer, 42:1612-22.
42. Lapidot T, Dar A, Kollet O. 2005. How do stem cells fi nd their way home? Blood 106:1901-10.
43. Leleu X, Xiaoying J, Runnels J, et al. 2007. The Akt pathway regulates survival and homing in Waldenström macroglobulinemia. Blood, 110:4417-26.
44. Mateos MV, Hernandez JM, Hernandez MT, et al. 2006. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood, 108:2165-72.
45. Mitsiades CS, Mitsiades N, Poulaki V, et al. 2002. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signalling in human multiple myeloma cells: therapeutic implications. Oncogene, 21:5673-83.
46. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. 2006. Antimyeloma activity of heat shock protein-90 inhibition. Blood, 107:1092-100.
47. Mitsiades N, Mitsiades CS, Poulaki V, et al. 2002. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 99:4525-30.
48. Mitsiades N, McMullan C, Poulaki V, et al. 2004. The mTOR inhibitor RAD001 (Everolimus) is active against multiple myeloma cells in vitro and in vivo [abstract]. Blood, 104:1496.
49. Moreau AS, Jia X, Ngo HT, et al. 2007. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenström's macroglobulinemia. Blood, 109:4964-72.
50. Moreau AS, Jia X, Leleu X, et al. 2007. Simvastatin, an HMG-CoA inhibitor, induces in vitro antitumor activity in Waldenström's macroglobulinemia [abstract]. Hematologica, 92:1219.
51. Moreau P, Voillat l, Benboubker L, et al. 2006. Rituximab in CD20 positive multiple myeloma: a prospective study from the IFM group [abstract]. Blood, 108:3577.
52. Ngo H, Hatjiharissi, E, Leleu, X, et al. 2006. The CXCR4/SDF-1 axis regulates migration and adhesion in Waldenström macroglobulinemia [abstract]. Blood, 108:2418.
53. O'Connor O, Orlowski, R, Alsina M, et al. 2006. Multicenter phase I studies to evaluate the safety, tolerability, and clinical response to intensive dosing with the proteasome inhibitor PR-171 in patients with relapsed or refractory hematological malignancies [abstract]. Blood, 108:2430.
54. Orlowski RZ, Zhuang SH, Parekh T, et al. 2006. The combination of pegylated liposomal doxorubicin and Bortezomib significantly improves time to progression of patients with relapsed/refractory multiple myeloma compared with Bortezomib alone: results from a planned interim analysis of a randomized phase III study [abstract]. Blood, 108:404.
55. Palladini G, Perfetti V, Obici L, et al. 2005. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood, 105:2949-51.
56. Palumbo A, Bringhen S, Caravita T, et al. 2006. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, 367:825-31.
57. Palumbo A, Falco P, Falcone A, et al. 2006. Oral revlimid plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: Results of a multicenter phase I/II study [abstract]. Blood, 108:800.
58. Patterson C, Soumerai J, Hunter Z, et al. 2006. Sildenafi l citrate suppresses disease progression in patients with Waldenström's macroglobulinemia. J Clin Oncol, 18S:7556.
59. Podar K, Raab MS, Zhang J, et al. 2006. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor Enzastaurin (LY317615.HCl). Blood, 109:1669-77.
60. Raje N, Kumar S, Hideshima T, et al. 2004. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood, 104:4188-93.
61. Rajkumar SV, Fonseca R, Dispenzieri A, et al. 2000. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc, 75:897-901.
62. Rajkumar SV, Hayman S, Gertz MA, et al. 2002. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol, 20:4319-23.
63. Rajkumar SV, Hayman SR, Lacy MQ, et al. 2005. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 106:4050-3.
64. Rajkumar SV, Blood E, Vesole D, et al. 2006. Eastern Cooperative Oncology Group Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol, 24:431-6.
65. Rajkumar SV, Blood E. 2006. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med, 354:2079-80.
66. Rajkumar V, Jacobus S, Callander N, et al. 2007. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood, 110:74.
67. Renaud S, Fuhr P, Schweikert GM, et al. 2006. High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology, 66:742-4.
68. Richardson PG, Barlogie B, Berenson J, et al. 2003. A phase 2 study of Bortezomib in relapsed, refractory myeloma. N Engl J Med, 348:2609-17.
69. Richardson PG, Schlossman RL, Weller E, et al. 2002. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100:3063-7.
70. Richardson PG, Sonneveld P, Schuster MW, et al. 2005a. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med, 352:2487-98.
71. Richardson P, Chanan-Khan A, Alsina M, et al. 2005b. Safety and activity of KOS-953 in patients with relapsed refractory multiple myeloma (MM): Interim results of a phase 1 trial [abstract]. Blood, 106:361.
72. Richardson PG, Mitsiades C, Hideshima T, et al. 2006a. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther, 6:1165-73.
73. Richardson PG, Blood E, Mitsiades CS, et al. 2006b. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 108:3458-64.
74. Richardson PG, Mitsiades C, Ghobrial I, et al. 2006c. Beyond single-agent Bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol, 18:598-608.
75. Richardson P, Lonial S, Jakubowiak J, et al. 2006d. A multicenter phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (Dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM) [abstract]. Blood, 108:3582.
76. Roccaro A, Leleu X, SAcco A, et al. 2008. Dual targeting of the proteasome regulates survival and homing in Waldenström's macroglobulinemia. Blood, 111:4752-63.
77. Roccaro A, Leleu X, Moreau AS, et al. 2008. Resveratrol exerts antiproliferative effect and induces apoptosis in Waldesntrom's macroglobulinemia. Clin Cancer Res, 14:1849-58.
78. Rossi J, Moreaux J, Rose M, et al. 2006. A Phase I/II study of atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed multiple myeloma (MM) or active previously treated Waldenström's macroglobulinemia (WM) [abstract]. Blood, 108:3578.
79. Sanchorawala V, Wright DG, Rosenzweig M, et al. 2007. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trail. Blood, 109:492-6.
80. San Miguel J, Schlag R, Khuageva O, et al. 2007. MMY-3002: A phase 3 study comparing Bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma [abstract]. Blood, 110:76.
81. Shi Y, Gera J, Hu L, et al. 2002. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res, 62:5027-34.
82. Siegel D, Krishnan A, Lonial S, et al. 2006. Phase II trial of SCIO-469 as monotherapy (M) or in combination with Bortezomib (MB) in relapsed refractory multiple myeloma (MM) [abstract]. Blood, 108:3580.
83. Singhal S, Mehta J, Desikan R, et al. 1999. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 341:1565-71.
84. Sitia R, Palladini G, Merlini G. 2007. Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica, 92:1302-7.
85. Spencer A, Prince HM, Roberts A, et al. 2007. Thalidomide improve survivals when use after ASCT [abstract]. Hematologica, 92(suppl 2):S7b.5.
86. Tai YT, Tong X, Santos D, et al. 2005. Human anti-CD40 antagonist antibody triggers signifi cant antitumor activity against human multiple myeloma. Cancer Res, 65:5898-906.
87. Tamburini J, Levy V, Chaleteix C, et al. 2005. Treatment of Waldenström's macroglobulinemia with the combination of fludarabine and cyclophosphamide: results in 49 patients. Leukemia, 19:1831-4.
88. Treon S, Branagan AR, Hunter Z, et al. 2004a. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenström's macroglobulinemia. Ann Oncol, 15:1481-3.
89. Treon S, Branagan A, Wasi P, et al. 2004b. Combination therapy with rituximab and fludarabine in Waldenström's macroglobulinemia [abstract]. Blood, 104:753.
90. Treon SP, Tournilhac O, Branagan AR, et al. 2004c. Clinical responses to sildenafi l in Waldenström's macroglobulinemia. Clin Lymphoma, 5:205-7.
91. Treon SP, Emmanouilides C, Kimby E, et al. 2005a. Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol, 16:132-8.
92. Treon S, Hansen M, Branagan AR, et al. 2005b. Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol, 23:474-81.
93. Treon SP, Gertz MA, Dimopoulos M, et al. 2006a. Update on treatment recommendations from the Third International Workshop on Waldenström's macroglobulinemia. Blood, 107:3442-6.
94. Treon SP, Soumerai J, Patterson C, et al. 2006b. Bortezomib, dexamethasone and rituximab (BDR) is a highly active regimen in the primary therapy of Waldenström's macroglobulinemia: planned interim results of WMCTG clinical trial 05-180 [abstract]. Blood, 108:2765.
95. Treon SP, Gertz MA, Dimopoulos M, et al. 2006c. Update on treatment recommendations from the Third International Workshop on Waldenström's macroglobulinemia. Blood, 107:3442-6.
96. Treon SP, Soumerai J, Patterson C, et al. 2006d. Imatinib mesylate (Gleevec) is active in relapsed/refractory Waldenströms macroglobulinemia: Planned interim results of WMCTG Clinical Trial 05-140 [abstract]. Blood, 108:2484.
97. Tsai D, Maillard I, Downs LH, et al. 2004. Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenström's macroglobulinemia. Leuk Lymphoma, 45:591-5.
98. van Oers MH, Klasa R, Marcus RE, et al. 2006. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood, 108:3295-301.
99. Weber D, Rankin K, Gavino M, et al. 2003a. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol, 21:16-19.
100. Weber DM, Dimopoulos MA, Delasalle K, et al. 2003b. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenström's macroglobulinemia. Semin Oncol, 30:243-7.
101. Weber D, Chen C, Niesvizky M, et al. 2006. Lenalidomide plus highdose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM- 009) [abstract]. J Clin Oncol, 18S:7521.
102. Zervas K, Mihou D, Katodritou I, et al. 2006. VAD-doxil vs VAD-doxil plus thalidomide as initial treatment in patients with multiple myeloma: a multicenter randomized trial of The Greek Myeloma Study Group [abstract]. Blood, 108:794.